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Oral cancer is one of the major global threats to public health. The development of oral cancer is a tobacco-related multistep
and multifocal process involving ﬁeld cancerization and carcinogenesis. The rationale for molecular-targeted prevention of oral
cancer is promising. Biomarkers of genomic instability, including aneuploidy and allelic imbalance, are possible to measure
the cancer risk of oral premalignancies. Understanding of the biology of oral carcinogenesis will yield important advances for
detecting high-risk patients, monitoring preventive interventions, and assessing cancer risk and pharmacogenomics. In addition,
novel chemopreventive agents based on molecular mechanisms and targets against oral cancers will be derived from studies using
appropriate animal carcinogenesis models. New approaches, such as molecular-targeted agents and agent combinations in high-
risk oral individuals, are undoubtedly needed to reduce the devastating worldwide consequences of oral malignancy.
1.Introduction
Head and neck cancer is the sixth most common human
cancer [1], representing 3% of all types of cancer. They
are located in the oral cavity in 48% of cases, and 90%
o ft h e s ea r eo r a ls q u a m o u sc e l lc a r c i n o m a[ 2]. They are
sometimes preceded by precancerous lesions, such as
leukoplakia and erythroplakia. More than 300,000 new cases
of oral squamous cell carcinoma are diagnosed annually [3].
Approximately 35,000 new cases are recorded annually in the
US [2], 40,000 new cases are recorded in the EU and 10915
new cases in Japan [4]. The most common site for intraoral
carcinoma is the tongue, which accounts for around 40%
of all cases in the oral cavity proper. Tongue cancers most
frequently occur on the posterior-lateral border and ventral
surfaces of the tongue. The ﬂoor of the mouth is the second
most common intraoral location. Less common sites include
the gingival, buccal mucosa, labial mucosa, and hard plate.
The incidence of oral cancer has signiﬁcant local varia-
tion. Oral and pharyngeal carcinomas account for up to half
of all malignancies in India and other Asian countries, and
thisparticularlyhighprevalenceisattributedtotheinﬂuence
of carcinogens and region-speciﬁc epidemiological factors,
especially tobacco and chewing betel quid. An increase in
the prevalence of oral cancer among young adults is a cause
of special concern. There has been a 60% increase in the
number of under 40 years olds with tongue cancer over past
30 years. However, little has been published on the etiology
and natural history of this increase [5]. Oral malignancy,
including tongue cancer, is associated with severe morbidity
and long-term survival of less than 50% despite advances in
the treatment (surgery, radiation, and chemotherapy) of oral
cancer. The survival of the patients remains very low, mainly
due to their high risk of developing a second primary cancer.
Therefore, the early detection and prevention of oral cancer
and premalignancy are quite important [6–10]. This article
will focus on the current understanding of oral carcinogene-
sis for the early detection and prevention of oral malignancy.
2. Oral Carcinogenesis
Oral carcinogenesis is a highly complex multifocal process
that takes place when squamous epithelium is aﬀected by
several genetic alterations. The use of several molecular2 Pathology Research International
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Figure 1: The natural history of oral carcinogenesis.
biology techniques to diagnose oral precancerous lesions
and cancer may markedly improve the early detection of
alterations that are invisible under the microscope. This
would identify patients at a high risk of developing oral
cancer [11]. The natural history of oral cancer and sequence
of genetic alterations are illustrated in Figure 1. There are
several approaches to understanding the molecular basis of
oral cancer [12–14]. They include microarray technology,
methylation microarrays, gene expression microarrays, array
comparative genomic hybridization, proteomics, mitochon-
drial arrays, and micro-RNA arrays [15]. High-throughput
approaches are currently being used to search for oral cancer
biomarkers in bioﬂuids, such as saliva and serum [15].
Field cancerization’ refers to the potential development
of cancer at multiple sites [16, 17]. This has been observed
during the development of cancer in the tissues covered
with squamous epithelium (head and neck tumor) and
transitional epithelium (urothelial carcinoma). It is evident
that oral cancer, like carcinomas in other tissues, develops
over many years, and during this period, there are multiple
sites of neoplastic transformation occurring throughout the
oral cavity. “Field cancerization” may also be deﬁned by the
expression of mutations in the exons of tumor suppressor
genes. One such tumor suppressor gene is p53, and muta-
t i o n so ft h i sg e n eh a v eb e e no b s e r v e di nv a r i o u ss i t e so f
premalignant leukoplakia and carcinoma in the same oral
cavity [18]. A reduction in tumor suppressor activity by the
gene and the development of mutations in p53 are associated
with smoking and an increased risk for oral carcinoma
development [19]. Therefore, multifocal presentations and
mutational expressions of tumor suppressor genes may be
the consequence of long-term (e.g., 20 ∼ 40 years) exposure
tovariousenvironmentalandexogenousfactors.Thecontin-
ual presence of mutations may also signify changes in DNA
repair and apoptosis, thereby increasing the susceptibility to
future transformation. Mutational adaptations that modify
the survivability of particular clones of transforming cells
mayalsofurtherenhancethelevelofresistancetotherapeutic
control. A recent genetic analysis revealed that cancers
developing at distant sites within the oral cavity often are
derived from the same initial clone [20]. The multiplicity of
the oral carcinogenesis process makes it diﬃcult to interrupt
the progression to cancer through the surgical removal of a
premalignant lesion.
3. Risk Factorsof Oral Cancer
The most important risk factor for the development of oral
cancer in the Western countries is the consumption of toba-
cco [21]a n da l c o h o l[ 22]. Although drinking and smoking
are independent risk factors, they have a synergistic eﬀect
and greatly increase the risk together. The use of smokeless
t o b a c c op r o d u c t ss u c ha sg u t k h aa n db e t e lq u i di nA s i a n
countries [5, 23] is responsible for a considerable percentage
of oral cancer cases.
3.1. Genetic. Several studies have reported a signiﬁcant
familial component in the development of oral cancer.
The estimates of risk in the ﬁrst degree relatives of oral
cancer patients vary widely and range from 1.1 [24]t o
3.8 [25], although some of these cancers refer to head
and neck cancer in general. Familial aggregation of oral
cancer, possibly with an autosomal dominant mode of
inheritance, is observed in a very small percentage of oral
cancer patients [26]. Polymorphic variation of genes in the
xenobiotic metabolism pathways such as in CYP1A1 or the
genes coding for glutathione S-transferase-M1 [27, 28]a n d
N-acetyltransferase-2 [29] may be implicated. Individuals
that carry the fast-metabolizing alcohol dehydrogenase
type 3 (ADH3)a l l e l e[ 30] may be particularly vulnerable
to the eﬀects of chronic alcohol consumption and could
be at increased risk to develop oral cancer [31]. The singlePathology Research International 3
nucleotide polymorphism A/G870 in the CCND1 gene that
encodes Cyclin D is associated with susceptibility to oral
cancer. The AA genotype [32] or the GG wild-type genotype
[33] may increase risk for oral cancer.
3.2. Inﬂammation. Cytokines, including interleukins (ILs),
tumor necrosis factors (TNFs), and certain growth factors,
are an important group of proteins that regulate and mediate
inﬂammationandangiogenesis.Tumorgrowth,invasionand
metastasis are facilitated when there is a deregulation in their
production. Genetic association studies suggest a putative
correlation between functional DNA polymorphisms in
cytokine genes and oral cancer [34]. Increased serum levels
of proinﬂammatory cytokines, interleukin (IL)-1β,I L - 6 ,I L -
8, and TNF-α as well as the anti-inﬂammatory cytokine,
IL-10, are seen in patients with oral cancer in comparison
to healthy controls. The anti-inﬂammatory cytokine IL-4
inhibitsoralcancerinvasionbythedownregulationofmatrix
metalloproteinase-9.
3.3. Infection. Human papillomavirus (HPV), particularly
HPV type 16, may be an etiologic factor, especially among
persons who do not smoke or drink alcohol [35, 36]. Ang
et al. [37] reported that tumor HPV status is a strong and
independent prognostic factor for survival among patients
with oropharyngeal cancer. They also noted that the risk
of death signiﬁcantly increased with each additional pack-
year of tobacco smoking. Although the idea that bacterial
infections could lead to oral cancer has been generally
discounted,thereisanincreasingbodyofevidencetosuggest
a possible relationship between micro-organisms and the
development of oral cancer. The mostnotable example is that
ofthecommonpathogenicbacteriumHelicobacterpyloriand
its association with gastric cancer. The mouth contains a
variety of diﬀerent surfaces that are home to a huge diversity
ofmicro-organisms,includingmorethan750distincttaxaof
bacteria, thus suggesting that the oral squamous epithelium
is constantly exposed to a variety of microbial challenges, on
both cellular and molecular levels. It is therefore important
to consider how such factors may be related to oral cancer
development [38, 39].
3.4. Preneoplasia. There are clinically apparent oral prema-
lignant lesions of oral cancer. They include leukoplakia,
erythroplakia, nicotine stomatitis and tobacco pouch ker-
atosis, lichen planus, and submucous ﬁbrosis, [40]. The
term “leukoplakia” was ﬁrst used by Schwimmer in 1877
[41] to describe a white lesion of the tongue that probably
represented a syphilitic glossitis. The deﬁnition of leuko-
plakia has often been confusing and controversial. Some
clinicians now avoid using this term. The World Health
Organization deﬁnes leukoplakia as ‘a white patch or plaque
that cannot be characterized clinically or pathologically as
any other disease [42]. Therefore, leukoplakia should be
used only as a clinical term. The term has no speciﬁc
histopathological connotation and should never be used as
a microscopic diagnosis. Leukoplakia is a clinical diagnosis
of exclusion. Sometimes a white patch is initially believed to
represent leukoplakia, but the biopsy reveals another speciﬁc
diagnosis. These lesions should no longer be categorized as a
leukoplakia. Leukoplakia is seen most frequently in middle-
aged and older males, with an increasing prevalence with
age [43]. Fewer than 1% of males below the age of 30 have
leukoplakia, but the prevalence increases to an alarming 8%
in men over the age of 70 [43]. The prevalence in females
past the age of 70 is approximately 2%t. The most common
sites are the buccal mucosa, alveolar mucosa, and lower lip.
However, lesions occurring on the ﬂoor of mouth, lateral
tongue,andlowerliparemostlikelytoshoweitherdysplastic
or malignant changes [44].
The term “erythroplasia” originally used by Queyrat [45]
todescribeared,precancerouslesionofthepenisisusedfora
clinically and histopathologically similar process that occurs
on the oral mucosa. Similar to the deﬁnition for leukoplakia,
erythroplakia is a clinical term that refers to a red patch
that cannot be deﬁned clinically or pathologically as any
other condition [42]. This deﬁnition excludes inﬂammatory
conditions that may result in a red clinical appearance.
Oral erythroplakia occurs most frequently in older males
and appears as a red macule or plaque with a soft, velvety
texture. The ﬂoor of mouth, lateral tongue, retromolar pad,
and soft palate are the most common sites of involvement.
Often the lesion is well demarcated, but some examples may
gradually blend into the surrounding mucosa. Some lesions
may be intermixed with white areas (erythroleukoplakia).
Erythroplakiaisoftenasymptomatic,althoughsomepatients
may complain of a sore, burning sensation.
3.5. Tobacco. Nicotine stomatitis is a thickened, hyperkera-
totic alteration of the palatal mucosa that is most frequently
related to pipe smoking, but milder examples can also
develop secondary to cigar smoking or, rarely, from cigarette
smoking [42]. The palatal mucosa becomes thickened and
hyperkeratotic, sometimes developing a ﬁssured surface. The
surface often develops numerous elevations with red centers,
which represent the inﬂamed openings of the minor salivary
gland ducts.
Another speciﬁc tobacco-related oral mucosal alteration
occurs in association with smokeless tobacco use, such as
either snuﬀ or chewing tobacco [40]. Such lesions typically
occur in the buccal or labial vestibule where the tobacco
is held, but they can also extend onto the adjacent gingiva
and buccal mucosa. Early lesions show slight wrinkling that
disappears when the tissues are stretched. Other lesions may
appear as hyperkeratotic, granular patches. Advanced lesions
exhibit greatly thickened zones of grayish white mucosa
with well-developed folds and ﬁssures. The degree of clinical
alteration depends on the type and quantity of tobacco, the
duration of tobacco usage, and host susceptibility. Smokeless
tobacco keratosis shows microscopic hyperkeratosis and
acanthosis of the mucosal epithelium. True epithelial dyspla-
sia is uncommon, and when dysplasia is found, it tends to be
mild [46].
3.6. Mutations. Genetic mutations often produce early phe-
notypic changes that may present as clinically apparent,
recognizable lesions. An oral premalignant lesion is an area4 Pathology Research International
of morphologically or genetically altered tissue that is more
likely than normal tissue to develop cancer. The reported
rates of malignant transformation of leukoplakia range
from less than 1% to 18% [47, 48]. There is no accepted
method to predict the risk of malignant progression of an
individual oral premalignant lesions, but various factors,
suchasthelocationwithintheoralcavity,clinicalappearance
(homogeneous versus heterogeneous), and the presence of
dysplasia are correlated with the risk of progression. The
histologicalﬁndingofdysplasiaisstronglyassociatedwithan
increased rate of invasive cancer development [47]. A velvety
reddishmucosallesion,knownaserythroplakia,isassociated
with a higher rate of cancer development, occurs much less
frequently, and is more diﬃcult to detect clinically than oral
leukoplakia. Virtually all erythroplakic lesions contain severe
dysplasia, carcinoma in situ, or early invasive carcinoma
at the time of presentation [49]. Formalized classiﬁcation
and staging systems for oral preneoplastic lesions have been
proposed [50, 51], and their use is important to facilitate
uniform reporting and comparisons of data.
Detection and diagnosis of oral neoplasia has tradition-
ally relied heavily on the clinical experience of the examiners
and their ability to recognize often subtle morphologic
changes.However,someearlymalignantlesionsareclinically
indistinguishable from benign lesions, and some patients
develop carcinomas in the absence of clinically identiﬁable
oral premalignant lesions. Furthermore, it can be diﬃcult,
even for experts, to determine which oral premalignant
lesions are at signiﬁcant risk to progress to invasive car-
cinoma. Therefore, an accurate, objective, and noninvasive
method to help identify premalignant lesions and to distin-
guish those at risk of malignant conversion is needed.
4. Biomarkers of Oral Cancer
Biomarkers help in evaluating the preventive measures or
therapies and the detection of the earliest stages of oral
mucosal malignant transformation. Biomarkers reveal the
genetic and molecular changes related to early, intermediate,
and late end-points in the process of oral carcinogenesis.
These biomarkers will reﬁne the ability to enhance the
prognosis, diagnosis, and treatment of oral carcinomas [52].
Genetic and molecular biomarkers will also determine the
eﬃcacy and safety of chemopreventive agents. Chemopre-
ventive agents are chemicals of natural or synthetic origin.
Unlikeotherdrugs,whichdonotpreventdisease,chemopre-
ventive agents reduce the incidence of diseases such as cancer
before clinical symptoms occur. This development is critical
for the understanding of early oral mucosal transformation.
Biomarkers will also reduce the number of patients and the
time for long-term follow-up required to deﬁne a signiﬁcant
clinical response to a chemopreventive agent [53, 54]. The
markers may therefore clarify the types, doses, frequencies,
and regimens to achieve the maximum level of beneﬁt
from chemopreventive agents. Decreasing the cost of the
clinical trials is another factor that drives the development
of biomarkers.
Biomarkers have been categorized following the recom-
mendation by the Committee on Biological Markers of the
National Research Council/National Academy of Sciences
[55]. They fall into broad groups that detect exposure, pro-
gression, susceptibility to carcinogens, and/or the responses
by the target cellular populations [54].
Oral cancer studies have a distinct advantage due the
anatomical access to the developing premalignant and
malignant lesions. One could readily analyze biopsies of the
p r i m a r yl e s i o na sw e l la sa p p a r e n t l yn o r m a lm u c o s a ls i t e s
to determine the levels of DNA adducts and oral cancer
risk. DNA adduct studies and cytogenetic analyses may also
provide evidence for altered structure and function of sus-
ceptibility sites in the DNA following DNA binding studies
of nuclear proteins such as p53.S o m es t u d i e sh a v ef o c u s e d
on microscopic cytogenetic and somatic mutation changes
as early biologic markers. One of the markers used to deﬁne
chromosomal aberrations is the staining for micronuclei in
exfoliated buccal mucosal cells [56]. Micronuclei have also
been used to evaluate the reversal of leukoplakia and the
eﬀectiveness of retinoids, carotenoids, and vitamin E [57,
58]. Other methods include the determination of aneuploidy
and the assessment of losses and gains of genetic material
particularly associated with somatic and sex chromosomes.
Other sites of chromosomal aberrations are found in sister
chromatid exchanges, and allele typic variations designated
by losses on chromosomes 3, 4, 5, 6, 8, 9, 11, 13, 17, and 19.
Some molecular biomarkers with potential diagnostic
relevance include DNA content and chromosome polysomy,
loss of heterozygosity, nucleolar organizer regions, histo-
blood group antigens, proliferation markers, increased
epidermal growth factor receptor (EGFR), and decreased
expression of retinoic acid receptor-β, p16, and p53 [59, 60].
Although a reliable, validated marker panel for providing
clinically useful prognostic information in oral premalignant
lesions patients has not yet been established, the advent
of high-throughput genomic and proteomic analysis tech-
niques may soon yield major advances toward a prognosti-
cally relevant molecular classiﬁcation system (Table 1).
5. AnimalModels for Oral Carcinogenesis
A variety of animals have been used for the study of tumor
growth, the process of carcinogenesis, and the preven-
tion/treatment research [8, 61–64]. The continual develop-
ment of transgenic or knockout mice has improved our
understanding of the role of speciﬁc genes in tumor growth.
The most widely used animal models for oral carcinogenesis
are the hamster cheek pouch model [62, 65] and the 4-
nitroquinoline 1-oxide- (4-NQO-) induced oral (tongue)
carcinogenesis model [8, 61, 66, 67].
DMBA is one of the widely used carcinogens in experim-
ental oral carcinogenesis. Induction of SCC in cheek pouch
of hamsters was ﬁrst described with the aid of three polyc-
yclic aromatic hydrocarbons, such as 7,12-dimethylbenz(a)-
anthracene (DMBA), 20-methyleholanthrene (20-MC), and
3,4-benzpyrene [68].Acomplete carcinogen,DMBA(0.5%),
is applied to the hamster cheek pouch three times a week
for 16 weeks. All animals exhibit invasive oral squamous cell
carcinoma by week 16. Many studies have been conducted
using the hamster buccal pouch model and thus elucidatedPathology Research International 5
Table 1: Potential biomarkers for oral carcinogenesis.
Category of biomarkers Measurements
Genomic Micronuclei, DNA adduct, DNA content, Chromosomal aberration
Oncogenic Oncogenic expression, Modiﬁed tumor suppressor genes, Src genes
Proliferation Nuclear and cyclin related antigens, Mitotic frequency, Ornithine decarboxylase (ODC), Polyamines
Diﬀerentiation Cytokeratins, Transglutaminase Type I, Transcription factor (AP)-1
Oxidative stress Glutathione S-transferase, Stress proteins (HSPs), Superoxide dismutase
Apoptosis Bcl-2 family, Chromatin condensation factors, Caspases, Mitochondrial pathway
Immunologic Various cytokines
an array of changes that are analogous to those observed
in human invasive oral carcinoma [62, 65]. These include
am u t a t i o ni nc o d o n6 1o fH a - ras, which manifested in an
A→T transversion in the second position of codon 61, thus
resulting in an amino acid change from glycine to leucine.
Theexpressionofc-Ki-ras inmalignanttumorsofthepouch,
but not in the normal oral mucosa, is also observed at
the very early stages of tumor development [65]. Although
the hamster oral tumor model appears to parallel several
changes observed in human oral cancer, the hamster still has
several areas of uniqueness which must be considered in any
evaluation of results from oral carcinogenesis studies. The
hamster cheek pouch provides a relatively large surface area
of oral mucosa for the development of invasive carcinoma,
while the human does not possess this type of mucosal
structure. In contrast to humans, mice, or rats, the hamster
cheek pouch lacks lymphatic drainage, which thus allows
various drugs or molecules to accumulate in the pouch. The
Syrian hamster population was also derived from a small
breeding pair that resulted in a restricted polymorphism for
the antigen recognition region (Ia region) and some of the
major histocompatibility K and D regions [69]. In addition,
the number of T-cells in the hamster spleen exhibits a lower
number/gram weight of the organ in comparison to the
mouse or human [69]. The hamster may also respond to
antigenic tumor sources with a natural killer macrophage
or granulocyte cytotoxicity rather than a T cell response
[69]. DMBA and its solvent vehicle (acetone or benzene)
are signiﬁcant local irritants that cause severe inﬂammatory
response, necrosis, and sloughing. Therefore, it is diﬃcult to
examine early squamous cell lesions [66, 70, 71]. Neoplasms
induced by DMBA in the hamster cheek pouch possess many
diﬀerences in histological features of diﬀerentiated SCC and
do not closely resemble the lesions observed in human [72,
73].
The latter animal models for the study of oral carcino-
genesis include those in rats and mice using the water sol-
uble carcinogen, 4-NQO. The carcinogen is supplied either
in the water (20ppm) for the rats [66, 71, 74–86]o rb y
painting for the mice [87]. The administration of 4-NQO
in drinking water (20ppm) for 8 weeks in rats and mice
produces tongue lesions including squamous cell neoplasms
within 32 weeks [83], while topical application of the carci-
nogen to the mouse palates for up to 16 weeks just like the
hamster model develops palate tumors within 49 weeks [87].
The 4-NQO-induced tongue carcinogenesis model is quite
useful for investigating oral carcinogenesis and identifying
cancer chemopreventive agents, because the most common
site for intraoral carcinoma is the tongue and the admin-
istration drinking water containing of 4-NQO is a simple
and easy method [66, 71, 74–86, 88–96]. Increased levels of
polyamine synthesis, as well as nucleolar organizer regions
(NORs) with the progression of oral carcinogenesis, have
been noted in the rat model [66]. The mouse model with 4-
NQO has demonstrated some molecular mimicry of human
oral cancers, as is true of the hamster model [87]. A
number of chemical carcinogens, including coal tar, 20-MC,
DMBA, and 4-NQO, have been used in experimental oral
carcinogenesis. However, 4-NQO is the preferred carcinogen
apart from DMBA in the development of experimental
oral carcinogenesis. 4-NQO is a water soluble carcinogen,
which induces tumors predominantly in the oral cavity. It
produces all the stages of oral carcinogenesis and several
lines of evidences suggest that similar histological as well
as molecular changes are observed in the human system.
There are several review articles that collate the available
information on the mechanisms of action of 4-NQO. In
addition, studies have been conducted for the development
of biomarkers and chemopreventive agents using 4-NQO
animal models [8–10, 61, 66, 67, 74–86].
The complexity and variety of biochemical changes that
can increase tumor development is demonstrated in the
p53−/− mice [97]. Unfortunately, this model and other
genetic mouse models have not been exploited for study-
ing the relationships among chemical oral carcinogenesis,
speciﬁc genetic defects, and chemoprevention. Genetically
altered mouse and rat models have been developed to
evaluatemolecular-targetedpreventionandtreatmentoforal
carcinoma [64]. The rasH2 transgenic mouse carcinogenesis
model [98]a n dh u m a nc - H a - ras proto-oncogene transgenic
rat model [99] have been developed for chemoprevention
studies on oral (tongue) carcinogenesis.
6. Chemoprevention
Chemoprevention is the use of natural or synthetic sub-
stances to halt, delay, or reverse malignant progression in
tissues at risk for the development of invasive cancer [8–10].6 Pathology Research International
Retinoids are the most extensively studied agents for chemo-
prevention of oral cancer [100]. Administration of 13-cis-
retinoic acid for only 3 months yields a clinical response
rate of 67% versus 10% for placebo. However, the toxicity is
considerable, and there is a very high rate of relapse within
3 months of stopping treatment. Subsequent studies with
retinoids in patients with oral premalignant lesions have
conﬁrmed clinical and pathologic response rates, though
toxicities remain a concern [101]. However, translational
studies show that molecular abnormalities persist in some
patients with a complete clinical and pathologic response
to retinoid therapy [102], suggesting that cancer devel-
opment may be delayed rather than prevented by these
agents. Other agents that have been assessed in clinical
trials to evaluate the chemoprevention activity in oral
leukoplakia patients include vitamin E [52], Bowman-Birk
inhibitor concentrate (BBIC) derived from soybeans [103],
curcumin [104], and green tea polyphenol epigallocatechin-
3-gallate. Small clinical trials using oral BBIC have
revealed no signiﬁcant toxicity and a 32% response rate
[103].
Attention is currently focused on the development of
agents targeted to speciﬁc steps in the molecular progression
from normal to oral premalignancy and to invasive carci-
noma. Examples of molecularly targeted agents that have
shown promise in vitro, in animal models, or in early clinical
trials include cyclooxygenase- (COX-) 2 inhibitors and epi-
dermal growth factor receptor (EGFR) inhibitors [105–107].
Data from several sources suggest that the cyclooxygenase
pathway is a good target for oral cancer prevention. COX-2 is
overexpressed in head and neck squamous carcinoma [108],
and COX-2 inhibitors prevent oral cancer development in
animal models [109]. A randomized placebo-controlled trial
of the COX-2 inhibitor ketorolac administered as an oral
rinse in oral leukoplakia patients revealed that the treatment
is well tolerated but does not result in a greater clinical
response than placebo [110]. However, an analysis of the
results of this trial is somewhat confounded by the high
response rate (32%) in the placebo arm and diﬃculty in
determining whether topical delivery of the agent allowed
penetration to the damaged cells. The future of COX-
2 inhibitors as chemoprevention agents will also depend
on determining the extent of risk for cardiac toxicities
associated with this class of agents. The EGFR is also a
promising molecular target for intervention in oral malig-
nant progression [105–107]. EGFR is a receptor tyrosine
kinase that is overexpressed in oral dysplasia and invasive
cancer and associated with poor prognosis in patients with
head and neck squamous carcinoma [111, 112]. EGFR
inhibitors, alone or in combination with chemotherapy and
radiotherapy, show activity against head and neck squamous
carcinoma in clinical trials and are generally well tolerated
[113]. Evidence suggests that combination therapy targeting
COX-2 and EGFR may be eﬃcacious [107, 114]. Although
chemoprevention appears to be a promising approach to
managing oral premalignancy, prospective clinical trials
using speciﬁc agents, and strong corollary translational and
laboratory investigations, are needed to evaluate clinical,
histological, and molecular eﬃcacy. It may be possible and
necessary to individualize medical therapy to speciﬁc genetic
abnormalities detected within the oral mucosa.
7. Conclusion
Human oral cancer is the sixth largest group of malignancies
worldwide. Seventy percent of oral cancers appear from
premalignantlesions.Theprocessofformationoforalcancer
results from multiple sites of premalignant change in the
oral cavity (ﬁeld cancerization). Animal models are now
being widely used for the development of diagnostic and
prognostic markers. The appearance of these premalignant
lesions is one distinct feature of human oral cancer. There
is currently a dearth of biomarkers to identify which of
these lesions will turn into malignancy. Regional lymph
node metastasis and locoregional recurrence are the major
factors responsible for the limited survival of patients with
oral cancer. The paucity of early diagnostic and prognostic
markers strongly contributes to the higher mortality rates.
Determining high- and low-risk populations by measuring
reliable biomarkers is expected to contribute to achieving
a better understanding the dynamics and prevention of
oral cancer development. The quantitation of genetic and
molecular changes and the use of these changes as markers
for the detection and prevention of early premalignant
change require the harvesting of tissues and cells. Promising
technologies are being rapidly developed to assist in the
identiﬁcation of an abnormal oral mucosa, noninvasive and
objective diagnosis and the characterization of identiﬁed
mucosal lesions, and in the therapies for patients with oral
cancer. Undoubtedly, the prevention or reduction in the
use of tobacco products and alcohol consumption would
have a profound inﬂuence on the incidence of oral cancer.
Chemoprevention also has an impact on the development of
malignant changes in the oral mucosa. Prevention through
chemoprevention and/or the use of systemic medications
is an extensively studied strategy and continues to hold
promise as a way of diminishing the morbidity and mortality
associated with this malignancy.
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